Dermata Therapeutics, Inc.
New Form D on file · 2026-01-07 · the record
What the record says
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 716 filings in Biotechnology, totalled by week. The dot is this raise, $4.12M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Use of proceeds, as written on the filing
Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.
Company officers on record
Gerald Proehl is named as Executive Officer and Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Kyri Van Hoose is named as Executive Officer on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Christopher Nardo is named as Executive Officer on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Maria Bedoya Toro Munera is named as Executive Officer on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
David Hale is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Wendell Wierenga is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Andrew Sandler is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Brittany Bradrick is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Kathleen Scott is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Mary Fisher is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
Steven Mento is named as Director on the Form D that Dermata Therapeutics, Inc. filed with the SEC on 7 January 2026, one of 11 people that filing names.
11 people named on the filing — 4 holding an executive role and 7 as directors only.
Named as of the 2026-01-07 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 11 people named on the filing — 4 holding an executive role and 7 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Dermata Therapeutics, Inc.
- Source Check — verify Gerald Proehl's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Gerald Proehl for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Dermata Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Dermata Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.